论文部分内容阅读
目的探讨重组促红细胞生成素(EPO)治疗慢性肾衰(CRF)贫血患者的疗效。方法对50例因CRF行血液透析治疗伴贫血的患者于血透结束时皮下注射EPO,配合福乃得治疗,作前后对比。结果患者治疗后红细胞压积(Hct)及Hb显著上升(P<0.01),其中显效30例(60%);有效17例(34%);无效3例(6%);总有效率达94%。结论EPO配合福乃得治疗CRF贫血疗效确切。
Objective To investigate the therapeutic effect of recombinant erythropoietin (EPO) on patients with chronic renal failure (CRF). Methods Fifty patients with anemia due to CRF hemodialysis were injected with EPO subcutaneously at the end of hemodialysis and were treated with fortunei before and after treatment. Results The hematocrit (Hct) and Hb in patients after treatment were significantly increased (P <0.01), of which 30 cases were markedly effective (60%), 17 cases were effective (34%), 3 cases were ineffective (6%), and the total effective rate was 94 %. Conclusions EPO combined with fortuneite is effective in treating CRF anemia.